为乳腺癌实施一致的治疗前多学科审查:质量改进项目
Karina Makarova1,2, Allison Chiu3, Rebecca Warburton4,2
1The University of British Columbia, Vancouver, Canada.
BMJ open quality
|February 15, 2026
概括
实施复杂乳腺癌病例的多学科预治疗审查显著改善了患者管理. 这种结构化的方法减少了治疗延迟,并导致近四分之一的被审查患者的护理直接发生变化.
科学领域:
- 在瘤学瘤学.
- 手术瘤学手术瘤学
- 医疗保健管理的管理
背景情况:
- 多模式和多学科的乳腺癌护理需要无的沟通.
- 缺乏结构化的沟通可能会导致患者的旅程障碍和治疗延迟.
- 改善复杂病例的多学科审查对于最佳的乳腺癌管理至关重要.
研究的目的:
- 增加在治疗前在多学科环境中审查的复杂乳腺癌病例的百分比.
- 在一个专门的乳腺计划中加强乳腺癌管理.
- 为了评估预治疗的有效性和影响,多学科的病例审查.
主要方法:
- 启动对瘤塑性乳房重建病例的审查,旨在在2023年5月之前进行50%的手术前审查.
- 将审查过程扩展到所有"复杂"乳腺癌病例,目标在2024年4月之前达到50%.
- 预期收集了对分类病例的数据,并进行了反调查,以评估过程的好处和挑战.
主要成果:
- 实现了对瘤塑性重建和所有复杂病例审查的研究目标.
- 23%的审查案件导致了患者管理的直接变化.
- 反调查表明,多学科审查过程的感知效益和可持续性.
结论:
- 多学科预治疗审查是改善乳腺癌管理的有效策略.
- 结构化的沟通和病例审查可以减轻治疗延迟,优化患者护理途径.
- 这些发现支持在复杂的瘤病例中整合定期的多学科团队会议.
更多相关视频
06:42Optimization of Breast Biopsy and Mastectomy Sample Collection Procedures for Biobanking, Personalized Medicine, and Research Applications
Published on: September 2, 2025
616
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
1.1K
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
